

Datasheet for ABIN7157699  
**anti-KRIT1 antibody (AA 471-585)**



[Go to Product page](#)

2 Images

## Overview

Quantity:	100 µg
Target:	KRIT1
Binding Specificity:	AA 471-585
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This KRIT1 antibody is un-conjugated
Application:	ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC)

## Product Details

Immunogen:	Recombinant Human Krev interaction trapped protein 1 protein (471-585AA)
Isotype:	IgG
Cross-Reactivity:	Human
Purification:	>95%, Protein G purified

## Target Details

Target:	KRIT1
Alternative Name:	KRIT1 ( <a href="#">KRIT1 Products</a> )
Background:	Background: Component of the CCM signaling pathway which is a crucial regulator of heart and vessel formation and integrity (By similarity). Negative regulator of angiogenesis. Inhibits

## Target Details

endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits ERK1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction, and cell junction stabilization. Plays a role in integrin signaling via its interaction with ITGB1BP1, this prevents the interaction between ITGB1 and ITGB1BP1. Microtubule-associated protein that binds to phosphatidylinositol 4,5-bisphosphate (PIP2)-containing membranes in a GTP-bound RAP1-dependent manner. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin-D1 (CCND1) levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels.

Aliases: Ankyrin repeat containing protein Krit1 antibody, CAM antibody, CCM 1 antibody, CCM1 antibody, Cerebral cavernous malformations 1 antibody, Cerebral cavernous malformations 1 protein antibody, Krev interaction trapped 1 antibody, Krev interaction trapped protein 1 antibody, KRIT 1 antibody, KRIT1 ankyrin repeat containing antibody, KRIT1 antibody, KRIT1\_HUMAN antibody

UniProt: [O00522](#)

Pathways: [Cell RedoxHomeostasis](#)

## Application Details

Application Notes: Recommended dilution: IHC:1:500-1:1000, IF:1:200-1:500,

Restrictions: For Research Use only

## Handling

Format: Liquid


Buffer: Preservative: 0.03 % Proclin 300  
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

## Handling


Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	-20 °C,-80 °C
Storage Comment:	Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

## Images



### Immunofluorescence

**Image 1.** Immunofluorescence staining of HepG2 cells with ABIN7157699 at 1:200, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).



### Immunohistochemistry

**Image 2.** IHC image of ABIN7157699 diluted at 1:600 and staining in paraffin-embedded human colon cancer performed on a Leica Bond™ system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.